In Friday’s Wall Street session, CureVac N.V (NASDAQ:CVAC) shares traded at $5.57, down -0.54% from the previous session.
CVAC stock price is now 49.79% away from the 50-day moving average and 68.97% away from the 200-day moving average. The market capitalization of the company currently stands at $1.25B.
With the price target maintained at $5, Jefferies recently Downgraded its rating from Buy to Hold for CureVac N.V (NASDAQ: CVAC). On April 25, 2024, Leerink Partners Downgraded its previous ‘Outperform’ rating to ‘Market Perform’ on the stock reducing its target price from $12 to quote $4, while ‘SVB Securities’ rates the stock as ‘Outperform’
In other news, Thaminda Ramanayake, affiliate bought 6,986 shares of the company’s stock on May 07 ’25. The stock was bought for $23,316 at an average price of $3.34. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 07 ’25, affiliate Myriam Mendila bought 17,839 shares of the business’s stock. A total of $88,019 was incurred on buying the stock at an average price of $4.93. A total of 58.26% of the company’s stock is owned by insiders.
During the past 12 months, CureVac N.V has had a low of $2.37 and a high of $5.72. As of last week, the company has a debt-to-equity ratio of 0.06, a current ratio of 7.65, and a quick ratio of 7.65. The fifty day moving average price for CVAC is $3.7186 and a two-hundred day moving average price translates $3.29635 for the stock.
The latest earnings results from CureVac N.V (NASDAQ: CVAC) was released for 2025-03-31. The net profit margin was 35.42% and return on equity was 34.46% for CVAC. The company reported revenue of $0.94 million for the quarter, compared to $13.43 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -92.99 percent.
